Back to top
more

Anavex Life Sciences (AVXL)

(Delayed Data from NSDQ)

$4.54 USD

4.54
792,261

+0.03 (0.67%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $4.54 0.00 (0.00%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Anavex Life Sciences (AVXL) Just Reclaimed the 50-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season

by Zacks Equity Research

Anavex Life Sciences (AVXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kevin Cook headshot

Alzheimer's Disease: 5 Stocks on Biotech Radars

by Kevin Cook

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.

Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.

Kevin Cook headshot

Biotech Bonanza: COVID Launches Science at Warp Speed

by Kevin Cook

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B

by Zacks Equity Research

Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes

by Zacks Equity Research

Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.

Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib

by Zacks Equity Research

Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

Illumina (ILMN) New Collaboration to Aid Genomics Startups

by Zacks Equity Research

Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.

Global Blood's (GBT) MAA for Oxbryta Accepted in Europe

by Zacks Equity Research

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.

Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

by Zacks Equity Research

Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.

Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

by Zacks Equity Research

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

Anavex Life Sciences (AVXL) Upgraded to Buy: Here's Why

by Zacks Equity Research

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anavex (AVXL) in Focus: Stock Moves 9.5% Higher

by Zacks Equity Research

Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

PPD Looks Good: Stock Adds 5.2% in Session

by Zacks Equity Research

PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Axonics (AXNX) Looks Good: Stock Adds 7.4% in Session

by Zacks Equity Research

Axonics (AXNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Personalis (PSNL) Looks Good: Stock Adds 8% in Session

by Zacks Equity Research

Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Principia (PRNB) Looks Good: Stock Adds 9.4% in Session

by Zacks Equity Research

Principia (PRNB) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Adverum (ADVM) Surges: Stock Moves 6.2% Higher

by Zacks Equity Research

Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AVXL) Outperforming Other Medical Stocks This Year?

Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.